Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 1/9/2010 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Daniel Rivera?

Daniel S. Rivera

Director of Molecular and Cellular Biology

Factor VIII

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Associate Director of Molecular Biology

EpiVax Inc


Web References(4 Total References)


www.epivax.com

EpiVax hopes to genetically modify Factor VIII so that it is not rejected by the bodies of hemophiliacs, said Daniel S. Rivera, the company's director of molecular and cellular biology.
"We've identified the regions responsible for the immune response, and now re-engineering the protein so you can give it to patients over and over again without any immunoreactive response," he said. Following the two-year program, EpiVax hopes it will have developed a new drug for hemophilia that it can start testing in large animals and then scale up for a clinical trial, Rivera said. Rivera credited the state's quasi-public Slater Technology Fund with providing seed funding that enabled EpiVax to develop the technology platform that he said is now driving the company's success. "They've been really instrumental throughout our entire growth process," he said.


www.epivax.com [cached]

Daniel Rivera


www.mvtimes.com [cached]

Julie McMurray, Epivax project manager, is returning to host an event similar to last year's, along with Dan Rivera, associate director of molecular biology at Epivax."The overall information we have now about tularemia is enormous, compared to even two years ago," Mr. Rivera said."We have a good idea of what the disease is and how to combat it.In addition to providing basic information about the disease and answering questions, Mr. Rivera and Ms. McMurray will provide an update on the Vineyard study.Ms. McMurray and Mr. Rivera also will discuss a request from the National Institutes of Health asking Epivax to collect tularemia samples for other researchers, as well."For a researcher to be able to get samples from such a controlled environment like the Island, it is such a valuable resource," Mr. Rivera said.


www.mvgazette.com [cached]

Once you've been exposed to the pathogen, you generate a memory, and the next time you see it, the body fights it better and you don't get sick," Daniel Rivera, the laboratory director at EpiVax and a molecular biologist, told the Gazette yesterday in a telephone interview. The blood sample needed is small, just eight to 10 tablespoons, said Mr. Rivera.Participants will be paid $100.Mr. Rivera said the blood from Islanders who have had tularemia is a key component to developing a vaccine.Scientists at EpiVax, working in concert with biologists at Brown University and Rhode Island Hospital, will extract T-cells from the blood and use them to develop the building blocks for a vaccine. "We expose them to these little synthetic peptides, and if they've seen tularemia before, they give a response, the cells will get turned on and secrete a protein immune response," said Mr. Rivera. That's phase one.If successful, phase two involves testing the vaccine on mice at the University of Massachusetts Medical School in Worcester.Mice would be vaccinated and then infected with tularemia.They would also be infected first and then treated with the vaccine to see if it was therapeutic after exposure to the bacteria, Mr. Rivera explained.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory